<DOC>
	<DOCNO>NCT00124280</DOCNO>
	<brief_summary>This study evaluate efficacy safety everolimus treatment patient advance NSCLC . The rationale investigate everolimus advance NSCLC previously treat chemotherapy chemotherapy plus EGFR inhibitor , like gefitinib erlotinib , base following : - The medical need well therapy advance NSCLC limit efficacy currently available therapy advance NSCLC . - Postulated association relevant cell-signaling pathway target everolimus different aspect oncogenesis , disease progression , response/resistance treatment . - Effectiveness everolimus rapamycin preclinical model lung cancer - Early report clinical response monotherapy mTOR inhibitor advance NSCLC . There evidence enhance PI3K/Akt/mTOR pathway , inhibit everolimus , may one key change account different aspect oncogenesis , disease progression , response/resistance NSCLC cancer treatment . The use mTOR inhibitor everolimus treatment advance NSCLC would novel therapeutic approach propose logically manipulate cell 's regulatory pathway enable control tumor growth .</brief_summary>
	<brief_title>Study Investigating Effect Everolimus Monotherapy Patients With Advanced Non-small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients advance ( unresectable metastatic ) NSCLC Tissue sample metastatic primary tumor available pathology evaluation molecular marker analyse Patients receive ≤ 2 chemotherapy regimen , one must include cisplatinum carboplatin , document evidence tumor progression ( Arm 1 ) Patients receive ≤ 2 chemotherapy regimen , one must include cisplatinum carboplatin well small molecule EGFR inhibitor ( separate regimen ) document tumor progression despite least 4 week therapy either gefitinib erlotinib ( Arm 2 ) Concurrent therapy agent use otherwise anticancer therapy ( example , methotrexate rheumatoid arthritis ) Any investigational drug , EGFR inhibitor ( Arm 2 ) , within precede 4 week Chronic treatment steroid another immunosuppressive agent Uncontrolled brain leptomeningeal metastasis , include patient continue require glucocorticoid brain leptomeningeal metastases Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Lung cancer</keyword>
	<keyword>non-small cell</keyword>
	<keyword>everolimus</keyword>
	<keyword>Non-small cell lung cancer ( NSCLC )</keyword>
</DOC>